格隆汇9月24日丨恒瑞医药(01276.HK)公告，9月24日耗资972.52万元回购14万股A股。 相关事件 恒瑞医药(01276.HK)9月24日耗资972.52万元回购14万股A股 恒瑞医药(01276.HK)获The Capital Group增 持172.82万股 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 呈交日期： 2025年9月24日 公司名稱： 江蘇恒瑞醫藥股份有限公司 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 A | | 於香港聯交所上市 | 否 | | | 證券代號 (如上市) | 600276 | 說明 | A股（於上海證券交易所上市） | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | 庫存股份變動 | | | | 事件 | | 已發行股份（不包括庫存股份）數 目 | 佔有關事件 ...

Group 1 - The A-share IPO market is active, with 72 companies listed by September 22, raising a total of 69.644 billion yuan, surpassing the total fundraising amount for the entire year of 2024 [2][3] - The Hong Kong market has seen 64 companies listed, raising a total of 146.887 billion HKD (approximately 134.325 billion yuan), exceeding the total for both 2023 and 2024 [2][3] - Deloitte's report indicates that the Hong Kong Stock Exchange will continue to lead global IPO financing rankings, driven by six large IPOs during the period [3][10] Group 2 - In the first three quarters, A-shares are expected to have 78 new IPOs raising 77.1 billion yuan, a 13% increase in the number of IPOs and a 61% increase in total fundraising compared to the same period last year [3][9] - The Hong Kong market is projected to have 66 new IPOs raising 1.823 billion HKD (approximately 1.668 billion yuan), representing a 228% year-on-year increase in fundraising [3][9] Group 3 - Major IPOs in 2023 include CATL, Zijin Mining International, Huadian New Energy, and others, with Huadian New Energy's IPO being the largest in A-shares this year at 18.1 billion yuan [5][11] - The A-share market is seeing a shift in industry focus, with traditional and high-end manufacturing sectors leading in both the number of IPOs and fundraising amounts [7][9] Group 4 - The number of IPO withdrawals has significantly decreased, with 83 companies withdrawing their IPOs this year, a 77.13% decline year-on-year [9] - As of September 19, there are 279 companies waiting for IPO approval in the A-share market, with 50 companies having been reviewed and 49 approved [9] Group 5 - The Hong Kong market is benefiting from policies encouraging mainland companies to list there and the optimization of the IPO application process, leading to a strong market momentum [10][13] - Deloitte forecasts that over 80 new IPOs will be listed in Hong Kong in 2025, raising between 250 billion to 280 billion HKD [13][14]

香港联交所最新资料显示，9月19日，The Capital Group Companies， Inc．增持恒瑞医药（01276） 172.82万股，每股均价87.2873港元，总金额约为1.51亿港元。增持后最新持股数目为1974.58万股，最新 持股比例为7.65%。 来源：新浪港股 ...

Group 1 - The Capital Group Companies, Inc. increased its stake in 恒瑞医药 (Hengrui Medicine) by acquiring 1.7282 million shares at an average price of HKD 87.2873 per share, totaling approximately HKD 151 million [1] - Following the acquisition, The Capital Group's total shareholding in 恒瑞医药 rose to 19.7458 million shares, increasing its ownership percentage from 6.98% to 7.65% [1][2]

智通财经APP获悉，香港联交所最新资料显示，9月19日，The Capital Group Companies, Inc.增持恒瑞医 药(01276)172.82万股，每股均价87.2873港元，总金额约为1.51亿港元。增持后最新持股数目为1974.58 万股，最新持股比例为7.65%。 ...

格隆汇9月23日丨恒瑞医药(01276.HK)公告，9月23日耗资8993.6万元回购129.8万股A股。 ...

智通财经APP讯，恒瑞医药(01276)发布公告，于2025年9月23日斥资8993.56万元回购129.8万股A股。 ...

呈交日期： 2025年9月23日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | A | 於香港聯交所上市 | 否 | | | 證券代號 (如上市) | 600276 | 說明 | A股（於上海證券交易所上市） | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 行股份（不包括庫存股 份）數目百分比 (註3) | 庫存股份數目 | 每股發行/出售價 (註4) | 已發行股份總數 | | 於下列日期開始時的結存(註1) | 20 ...

Core Viewpoint - Heng Rui Medicine's subsidiary Chengdu Shengdi Pharmaceutical has received approval from the National Medical Products Administration for the clinical trial of HRS-3095 tablets, aimed at treating chronic spontaneous urticaria (CSU) [1] Group 1: Clinical Trial Approval - The clinical trial application for HRS-3095 tablets was accepted on July 7, 2025, and has met the requirements for drug registration [1] - The drug is designed for patients suffering from chronic spontaneous urticaria (CSU) [1] Group 2: Drug Development - HRS-3095 tablets are a self-developed small molecule compound targeting immune cells, showing promising therapeutic effects for allergic diseases [1] - Preclinical data indicates that HRS-3095 can effectively improve skin allergy symptoms in mice [1] - Currently, there are no approved drugs targeting the same mechanism for CSU in both domestic and international markets [1] Group 3: Research Investment - The total research and development investment for the HRS-3095 project has reached approximately 16.03 million yuan [1]